瑟瑞妥單抗
瑟瑞妥單抗（INN：Seribantumab[1]；開發代號：MM-121）是一種單克隆抗體，設計用於治療癌症。[2]它與HER3的胞外結構域結合，阻斷NRG1結合，從而阻止受體的激活。[3]
| 單克隆抗體 | |
|---|---|
| 種類 | ? |
| 目標 | HER3 |
| 臨床資料 | |
| 其他名稱 | MM-121 |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1334296-12-6 |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6340H9810N1690O1986S52 |
| 摩爾質量 | 143,151.18 g·mol−1 |
參考資料
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108 (PDF). WHO Drug Information. 2012, 26 (4) [2024-03-01]. （原始內容存檔 (PDF)於2016-05-18）.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab, American Medical Association.
- ^ Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y. Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?. Biomedicines. August 2022, 10 (9): 2113. PMC 9495728
. PMID 36140214. doi:10.3390/biomedicines10092113 .
